In this episode, David Drapkin interviews Jim Gilligan: Interim CEO and Chief Scientific Officer of Tryp Therapeutics, a biotech company researching new compounds and delivery mechanisms for the treatment of eating disorders and nociplastic pain (fibromyalgia, phantom limb syndrome, complex regional pain syndrome). Tryp is currently running exploratory studies with oral psilocybin to collect enough data to move forward with their next step; the development (and bringing to market) of TRP-8803: a novel delivery mechanism for psilocybin that he believes will allow clinicians to know when the psychedelic experience will kick in, control how long it lasts, end the experience if the patient needs it, or extend it if they believe the patient will benefit. He also talks about how the neural network seems to hold onto memories (whether they’re accessible or not); the therapy factor and ways to manage long-term efficacy; Prader-Willi syndrome and hypothalamic obesity; the unfortunate necessity of patents to the companies spending millions trying to bring a drug to market; and why, in a newly-risky psychedelic market, he believes Tryp is a safe bet.

The post PT350 – Jim Gilligan – Psilocybin and Accessing the “Off” Switch For Nociplastic Pain appeared first on Psychedelics Today.

Previous articleMindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
Next articleMindMed Completes 1-for-15 Reverse Share Split